New Biomarkers Improving Cervical Cancer Screening Efficacy

New Biomarkers Improving Cervical Cancer Screening Efficacy

Carcinoma of the uterine cervix is the third most commonly diagnosed malignant neoplasm in women and the second cancerrelated cause of deaths in many low-resources geographical areas. Cervical cancer cytological screening programs, since the introduction in clinical practice of the Papanicolaou vaginal smear– the Pap test – have represented one of the major public health advantages and improvements of the last century; where cervical cancer screening is realized, incidence and mortality due to this disease have demonstrated a dramatic reduction. Despite this observation, invasive cervical cancer still accounts for almost 500,000 new cases per year worldwide, with approximately 11,000 and 4,000 new cases and deaths respectively in the USA per year.